Susanne Dudman
   Medical Microbiologist
   University Hospital
Fields of Expertise:
Diagnostics
SUBJECTS OF INTEREST

POSITIONS
Professor

University of Oslo





BIOGRAPHY

  • Professor of Virology, Inst. of Clinical Medicine, University of Oslo, Norway
  • Senior consultant Oslo University Hospital
  • Leader Norwegian Society for Virology
  • Councilor European Society for Clinical Virology (www.escv.eu)
  • Editor of Journal ... Read more
  • Professor of Virology, Inst. of Clinical Medicine, University of Oslo, Norway
  • Senior consultant Oslo University Hospital
  • Leader Norwegian Society for Virology
  • Councilor European Society for Clinical Virology (www.escv.eu)
  • Editor of Journal of Clinical Virology
  • Project leader of HEV vaccine trial in Bangladesh

SCIENTIFIC TRAININGS & EDUCATION

  • 1998-01-01 - 2003-06-01

    University of Oslo

  • 2002-09-01 - 2007-01-01

    Akershus University Hospital

  • 1994-01-01 - 2000-01-01

    Norwegian Medical Association

POSITIONS
  • 01.01.2019 -
Professor

University of Oslo

KEY PUBLICATIONS | ALL PUBLICATIONS

Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial

Joakim Øverbø, Asma Aziz, K Zaman, John Clemens, Cathinka Halle Julin, Firdausi Qadri, Kathrine Stene-Johansen, Rajib Biswas, Shaumik Islam, Taufiqur Rahman Bhuiyan, Warda Haque, Synne Sandbu, Manzoor E Elahee, Mohammad Ali, Jennifer L Dembinski, Susanne Dudman

Publication: Vaccine 2023


Safety and effectiveness of a recombinant hepatitis E vaccine among women of childbearing age: a cluster randomized, double-blind controlled, phase 4 trial in rural Bangladesh.

Zaman K, Julin CH, Aziz AB, Stene-Johansen K, Yunus M, Qadri F, Gurley ES, Sandbu S, Øverbø J, Dembinski JL, Laake I, Bhuiyan TR, Rahman M, Haque W, Khanam M, Clemens JD and Dudman S*.

Publication: Lancet Global Health

19 460 participants were enrolled and received either HEV239 or Hepa-B of whom 92·2% received three doses. HEV239 was safe and well tolerated in non-pregnant women, but findings regarding miscarriage warrant further investigation.


Receipt of hepatitis E vaccine and fetal loss in rural Bangladesh: further analysis of a double-blind, cluster-randomised, controlled trial.

Aziz AB, Dudman S, Julin CH, Ahmmed F, Stene-Johansen K, Sandbu S, Øverbø J, Dembinski JL, Wisløff T, Rana S, Basunia AH, Haque W, Qadri F, Zaman K, Clemens JD.

Publication: Lancet Global Health


My latest published articles
INTERESTS